Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Free Subscription


1 Cephalalgia
3 Headache
2 Lancet
1 Lancet Neurol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles


  1. KUAN AS, Chen SP, Wang YF, Fuh JL, et al
    Risk factors and psychological impact of syncope in migraine patients.
    Cephalalgia. 2019 Jul 15:333102419865253. doi: 10.1177/0333102419865253.
    PubMed     Text format     Abstract available


  2. MATHEW PG, Klein BC
    Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.
    Headache. 2019 Jul 18. doi: 10.1111/head.13601.
    PubMed     Text format     Abstract available

  3. LAW EF, Powers SW, Blume H, Palermo TM, et al
    Screening Family and Psychosocial Risk in Pediatric Migraine and Tension-Type Headache: Validation of the Psychosocial Assessment Tool (PAT).
    Headache. 2019 Jul 18. doi: 10.1111/head.13599.
    PubMed     Text format     Abstract available

  4. SPANOU I, Bougea A, Liakakis G, Rizonaki K, et al
    Relationship of Migraine and Tension-Type Headache With Hypothyroidism: A Literature Review.
    Headache. 2019 Jul 16. doi: 10.1111/head.13600.
    PubMed     Text format     Abstract available


    Rimegepant oral disintegrating tablet for migraine.
    Lancet. 2019 Jul 12. pii: S0140-6736(19)31611.
    PubMed     Text format    

  6. CROOP R, Goadsby PJ, Stock DA, Conway CM, et al
    Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Lancet. 2019 Jul 12. pii: S0140-6736(19)31606.
    PubMed     Text format     Abstract available

    Lancet Neurol

    The pain of a migraine.
    Lancet Neurol. 2019 Jul 12. pii: S1474-4422(19)30272.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.